KOSDAQ - Delayed Quote KRW
NeoPharm CO., LTD. (092730.KQ)
12,970.00
-70.00
(-0.54%)
At close: 3:30:25 PM GMT+9
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
119,013,743.69
119,013,743.69
97,104,890.49
85,033,138.23
87,930,719.73
Cost of Revenue
44,986,670.20
44,986,670.20
31,719,585.28
26,653,114.19
25,544,405.42
Gross Profit
74,027,073.49
74,027,073.49
65,385,305.21
58,380,024.04
62,386,314.31
Operating Expense
49,373,659
49,373,659
40,078,000
36,941,234
39,955,469
Operating Income
24,653,414.49
24,653,414.49
25,307,305.21
21,438,790.04
22,430,845.31
Net Non Operating Interest Income Expense
4,114,323.17
4,114,323.17
4,566,602.21
2,068,051.53
1,138,055.64
Pretax Income
30,208,776.50
30,208,776.50
29,373,287.45
23,323,213.22
23,835,607.71
Tax Provision
7,144,024.89
7,144,024.89
6,160,491.34
6,296,173.49
6,122,331.94
Net Income Common Stockholders
23,064,751.60
23,064,751.60
23,212,796.11
17,027,039.73
17,713,275.76
Basic EPS
1.48k
--
742.00
1.09k
1.13k
Diluted EPS
1.48k
--
742.00
1.09k
1.13k
Basic Average Shares
15,637.12
--
15,642.05
15,642.66
15,640.86
Diluted Average Shares
15,637.12
--
15,642.05
15,642.66
15,640.86
Total Operating Income as Reported
24,653,414.36
24,653,414.36
25,307,304.73
21,438,790.39
22,430,845.31
Total Expenses
94,360,329.20
94,360,329.20
71,797,585.28
63,594,348.19
65,499,874.42
Net Income from Continuing & Discontinued Operation
23,064,751.60
23,064,751.60
23,212,796.11
17,027,039.73
17,713,275.76
Normalized Income
23,410,505.54
23,410,505.54
23,468,007.93
17,247,315.32
18,010,821.48
Interest Income
4,155,104
4,155,104
4,587,925
2,076,894
1,176,513
Interest Expense
40,780
40,780
21,323
8,843
38,457
Net Interest Income
4,114,323.17
4,114,323.17
4,566,602.21
2,068,051.53
1,138,055.64
EBIT
30,249,556.50
30,249,556.50
29,394,610.45
23,332,056.22
23,874,064.71
EBITDA
33,399,348.84
33,399,348.84
31,067,794.02
24,948,403.79
25,374,331.54
Reconciled Cost of Revenue
44,986,670.20
44,986,670.20
31,719,585.28
26,653,114.19
25,544,405.42
Reconciled Depreciation
3,149,792.34
3,149,792.34
1,673,183.57
1,616,347.57
1,500,266.83
Net Income from Continuing Operation Net Minority Interest
23,064,751.60
23,064,751.60
23,212,796.11
17,027,039.73
17,713,275.76
Total Unusual Items Excluding Goodwill
-452,847
-452,847
-322,943
-301,728
-400,388
Total Unusual Items
-452,847
-452,847
-322,943
-301,728
-400,388
Normalized EBITDA
33,852,195.84
33,852,195.84
31,390,737.02
25,250,131.79
25,774,719.54
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-107,093.06
-107,093.06
-67,731.18
-81,452.41
-102,842.28
12/31/2021 - 1/30/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade